Core trials
Trials open to recruitment
![IDEA-FAST](/sites/default/files/2020-02/cropped-IDEA-FAST-logo3-2.jpeg)
IDEA-FAST
For patients with chronic diseases such as neurodegenerative disorders and immune-mediated inflammatory diseases, a key attribute for any successful therapeutic intervention is its ability to improve the patients’ activities of daily living (ADL…
![SINAPPS 2 Logo](/sites/default/files/2019-11/SINAPPS2_logo_5.jpg)
SINAPPS2
Psychosis and schizophrenia are caused by factors associated with excess dopamine and abnormally low N-methyl D-aspartate receptor (NMDAR) functioning. There is increasing evidence for the role of inflammation in these disorders. We propose that…
![PHOSPHATE logo](/sites/default/files/2024-02/Phosphate.png)
The PHOSPHATE Trial
Binding of intestinal phosphate in patients with KF has been practiced for more than half a century. Today, 88% of UK dialysis patients require binders to achieve treatment targets. Although dialysis is a life-sustaining therapy, the death rate…
![SimplifieD](/sites/default/files/2018-03/simplified_logo.jpg)
The SIMPLIFIED Registry Trial
In the United Kingdom, nearly 30,000 people receive regular dialysis and 6,000 new patients start dialysis each year. Although this is a life-saving treatment, dialysis-requiring renal failure carries a worse prognosis than most malignancies, …
![TURING Logo](/sites/default/files/2019-12/Turing.jpg)
TURING
Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) are auto-immune renal diseases that present with a common clinical phenotype, the nephrotic syndrome (NS), characterised by heavy proteinuria and debilitating oedema. When…